The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Open accessAbstract
To convert the values for low-density lipoprotein (LDL) cholesterol to millimoles per liter, multiply by 0.02586.† Included in this category is the number of patients who underwent randomization and received at least one dose of a study drug.‡ Patients who were enrolled in phase 2 parent trials and who agreed to participate in the extension study were enrolled in OSLER-1.§ Patients who were enrolled in phase 3 parent trials and who agreed to participate in the extension study were enrolled in OSLER-2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“with one agent showing benefit only among patients who had a baseline LDL cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter). 12”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both our trial and the SPIRE trial showed a more prominent absolute reduction in the risk of cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 100 mg or more per deciliter. 12”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the initial trials of these drugs, the incidence of neurocognitive adverse events (including delirium, cognitive and attentional disturbances, dementia, thought and perceptual disturbances, and psychiatric disorders) was very low (<1%) but slightly higher albeit non-significantly in the treated groups compared with placebo (0.9% vs. 0.3% for evolocumab) (81) (1.2% vs. 0.5% for alirocumab) (82).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, there were little more than 100 events in these studies combined.”
From Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (2017) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, exploratory data from longer-term follow-up in phase 2 and phase 3 trials of PCSK9 inhibitors showed significant reductions in cardiovascular outcomes.9,10”
From Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (2017) · cites this paper as [9]
In the citing paper
“No major effect on HDL-C has been reported, while TGs may increase in some predisposed patients [274].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [274]
In the citing paper
“At the top daily dose of 24 g of cholestyramine, 20 g of colestipol, or 4.5 g of colesevelam, a reduction in LDL-C of 18-25% has been observed.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [274]
In the citing paper
“Proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibitors and nicotinic acid reduce Lp(a) by ≏ 30%. 115-117”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“The efficacy at reducing LDL-C is in the range of 50-70%, independent of the presence of a background therapy (statins, ezetimibe, etc.); preliminary data from phase 3 trials suggest a reduction of CV events in line with the LDL-C reduction achieved.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“Recent data with PCSK9 inhibitors indicate a similar efficacy in reducing LDL-C in women vs. men. 115,116”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“Results in studies with PCSK9 inhibitors that included post-ACS/very high-risk patients were promising 115,116 and definitive outcome studies are awaited.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“The efficacy at reducing LDL-C is in the range of 50e70%, independent of the presence of a background therapy (statins, ezetimibe, etc.); preliminary data from phase 3 trials suggest a reduction of CV events in line with the LDL-C reduction achieved.115,116”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“Recent data with PCSK9 inhibitors indicate a similar efficacy in reducing LDL-C in women vs. men.115,116”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“Combination therapy using statin and ezetimibe prevents ASCVD incidence in patients with ACS. (Evidence level 1+, recommendation level: B).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [636]
In the citing paper
“The IMPROVE-IT study636) which enrolled ACS subjects (secondary prevention) with controlled LDL-C levels (50–100 mg/dL) under simvastatin treatment, revealed a significantly lower ASCVD incidence in the group for which ezetimibe was added on to simvastatin treatment.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [636]
In the citing paper
“Regarding the LDL-C management target, the IMPROVE-IT636) study revealed that lowering the LDL-C level to 53.6 mg/dL using statin–ezetimibe combination therapy suppressed cardiovascular events by 6.4% more than the group that had their LDL-C level controlled at 69.5 mg/dL with statins only.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [636]
In the citing paper
“(10,11).These agents dramatically reduce LDL-C levels over and above statin therapy, with favorable short-term outcomes data up to 18 months (11,12).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Self-citationEffects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Cited by
Sorted by citations
Items 901–1,000 of 1,004
Advanced in Molecular Mechanisms of Atherosclerosis: From Lipids to Inflammation
Meiliana, A., Dewi, N. M., & Wijaya, A. (2018) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v10i2.479 · Cited by 11
The New Face of Hyperlipidemia and the Role of PCSK9 Inhibitors
Nicholls, S. J. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1103-2 · Cited by 10
Brandts, J., & Müller‐Wieland, D. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0802-x · Cited by 9
Biotechnology Approaches for the Treatment of Dyslipidemia
Parolini, C. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07017-6 · Cited by 10
The effect of temperature on the stability of PCSK-9 monoclonal antibody: an experimental study
Kongmalai, T., Chuanchaiyakul, N., Sripatumtong, C., Tansit, T., Srinoulprasert, Y., Klinsukon, N., & Thongtang, N. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01447-3 · Cited by 10
Mendelsohn, A. R., & Larrick, J. W. (2016) · Rejuvenation Research · doi:10.1089/rej.2016.1849 · Cited by 9
Subramanian, S., & Chait, A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65798-7 · Cited by 9
Age of onset in genetic prion disease and the design of preventive clinical trialsPreprint
Minikel, E. V., Vallabh, S. M., Orseth, M. C., Brandel, J., Haı̈k, S., Laplanche, J., Zerr, I., Parchi, P., Capellari, S., Safar, J., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/401406 · Cited by 9
Mct11 deficiency alters hepatic glucose metabolism and energy homeostasisPreprint
Ainbinder, A., Zhao, L., Glover, P., Gelinas-Roa, K., Rusu, V., Harney, A. M., Hoch, E., Deik, A., Pierce, K. A., Bullock, K. H., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.08.459307 · Cited by 9
Ference, B. A. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1163 · Cited by 8
Nawaka, N., Rattanawan, C., Pussadhamma, B., Wutthimanop, A., Nuinoon, M., Porntadavity, S., Theansun, W., & Jeenduang, N. (2023) · Postgraduate Medicine · doi:10.1080/00325481.2023.2182579 · Cited by 8
Fatima, E., Qureshi, Z. A., Khanzada, M., Safi, A., Rehman, O. U., & Altaf, F. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00654-4 · Cited by 8
PCSK9 Monoclonal Antibodies Have Come a Long Way
Zendjebil, S., & Steg, P. G. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01243-1 · Cited by 8
Safety of Inclisiran: A Disproportionality Analysis from the EudraVigilance Database
Cicala, G., Rottura, M., Gianguzzo, V. M., Cristiano, F., Drago, S. F. A., Pallio, G., Irrera, N., Imbalzano, E., Spina, E., & Arcoraci, V. (2024) · Pharmaceuticals · doi:10.3390/ph17101365 · Cited by 8
Iannuzzo, G., Kamboj, G., Barman, P., Dongare, S., & Jawla, S. (2024) · Atherosclerosis Plus · doi:10.1016/j.athplu.2024.10.001 · Cited by 10
Targeted Therapies: The Role of Monoclonal Antibodies in Disease Management
Salah, A. N., Hashem, A. H., Zaki, M. B., Abulsoud, A. I., Atta, A. M., Elkalla, W. S., Moustafa, H. A. M., El‐Dakroury, W. A., El-Tokhy, F. S., ElBoghdady, J. A., et al. (2025) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70163 · Cited by 9
Atherosclerotic plaque, cardiovascular risk, and lipid-lowering strategies: a narrative review
Tam, F. C.-C., Lin, M.-G., Lam, T.-H., Tse, H.-F., & Wong, C. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1659228 · Cited by 16
Langslet, G. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw098 · Cited by 8
Genetics for the Identification of Lipid Targets Beyond PCSK9
Wang, L. R., & Hegele, R. A. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.11.003 · Cited by 8
Yuet, W. C., Ebert, D., & Jann, M. (2021) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098620959271 · Cited by 8
Blumenthal, D. M., Maddox, T. M., Aragam, K. G., Sacks, C. A., Virani, S. S., & Wasfy, J. H. (2021) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.120.007237 · Cited by 8
A bibliometric analysis of PCSK9 inhibitors from 2007 to 2022
Luo, Q., Tang, Z., Wu, P., Chen, Z., Fang, Z., & Luo, F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1218968 · Cited by 9
PCSK9 vaccines: a promising new strategy for the treatment of hypercholesterolemia?
Chackerian, B., & Remaley, A. T. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100524 · Cited by 8
Kayani, T., Ahmad, B., Chang, R., Qian, F., Sahinoz, M., Rehan, M., Giaimo, A., Spatz, E. S., & Hu, J. (2024) · Pharmacoepidemiology · doi:10.3390/pharma3010009 · Cited by 9
Emerging roles of PCSK9 in kidney disease: lipid metabolism, megalin regulation and proteinuria
Hummelgaard, S., Kresse, J., Jensen, M. S., Glerup, S., & Weyer, K. (2025) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-025-03069-5 · Cited by 8
PCSK9 Inhibition to Lower LDL-Cholesterol and Reduce Cardiovascular Risk
Waters, D. D., & Hsue, P. Y. (2015) · Circulation Research · doi:10.1161/circresaha.115.306493 · Cited by 8
Potential of PCSK9 as a new target for the management of LDL cholesterol
Mombelli, G. G., Pavanello, C., & Castelnuovo, S. (2015) · Research Reports in Clinical Cardiology · doi:10.2147/rrcc.s52961 · Cited by 8
Waite, L. H., Phan, Y. L., & Spinler, S. A. (2016) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2015.12.017 · Cited by 8
Cholesterol Management in the Era of PCSK9 Inhibitors
Svatikova, A., & Kopecky, S. L. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0891-5 · Cited by 8
Han, J., Wang, X., Ye, P., Cao, R., Yang, X., Xiao, W., Zhang, Y., Bai, Y., & Wu, H. (2017) · Journal of Human Hypertension · doi:10.1038/jhh.2017.56 · Cited by 8
Should an LDL-Cholesterol Target–Based Approach Be Readopted?
White, C. M., Weeda, E. R., & Nguyen, E. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017722009 · Cited by 8
Effects of Evolocumab on Cardiovascular Events
Mikhail, N. E. (2017) · Current Cardiology Reviews · doi:10.2174/1573403x13666170918165713 · Cited by 9
Low-Density Lipoprotein Cholesterol After an Acute Coronary Syndrome: How Low to Go?
Qamar, A., & Libby, P. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1160-6 · Cited by 8
Yokote, K., Suzuki, A., Li, Y., Matsuoka, N., & Teramoto, T. (2019) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cp203418 · Cited by 8
Genomic Medicine: Lessons Learned From Monogenic and Complex Bone Disorders
Trajanoska, K., & Rivadeneira, F. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.556610 · Cited by 8
Huang, K., Wen, X.-Q., Ren, N., Yang, L., & Gao, B. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2202052 · Cited by 8
Kang, S., Kim, K., Jun, S., Lee, S., Kim, J., Shin, J., Kim, Y., Kim, M., Park, S.-G., & Kang, N. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122006 · Cited by 8
Yang, W., Cai, X., Lin, C., Lv, F., Zhu, X., Han, X., & Ji, L. (2022) · Medicine · doi:10.1097/md.0000000000030563 · Cited by 8
Seijas‐Amigo, J., Cordero, A., Olmo, R. F., Quiroga, G. A. C., Fácila, L., Salgado‐Barreira, Á., Reyes-Santías, F., Romero‐Menor, C., Rondán, J., Rodríguez‐Mañero, M., et al. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001365 · Cited by 8
Bellino, M., Galasso, G., Silverio, A., Tedeschi, M., Formisano, C., Romei, S., Esposito, L., Cancro, F. P., Vassallo, M. G., Accarino, G., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082922 · Cited by 10
Gherasie, F.-A., Popescu, M. R., & Bartos, D. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13060944 · Cited by 8
Gottlieb, S., Kolker, S., Nir, S., Matetzky, S., Leitersdorf, E., Segev, A., Goldenberg, I., Tzivoni, D., Weisz, G., & Moriel, M. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.02.088 · Cited by 8
Revisiting Outcomes–Based Pricing Propositions for the PCSK9 Inhibitor Evolocumab
Hernandez, I. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.3143 · Cited by 8
Evolocumab for the treatment of hypercholesterolemia
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1365134 · Cited by 8
Schlunk, F., Fischer, P., Princen, H. M. G., Rex, A., Prinz, V., Foddis, M., Lütjohann, D., Laufs, U., & Endres, M. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112875 · Cited by 10
Experimental Biology for the Identification of Causal Pathways in Atherosclerosis
Guo, Y., Garcia-Barrio, M. T., Wang, L., & Chen, Y. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6644-7 · Cited by 8
Characteristics and Vascular Complications of Familial Hypercholesterolemia in Korea
Lee, S. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.34363 · Cited by 8
Cardiovascular Risk Beyond Low-Density Lipoprotein Cholesterol
Mayr, M., Gerszten, R. E., & Kiechl, S. J. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.12.040 · Cited by 9
A review on the efficacy and safety of lipid-lowering drugs in neurodegenerative disease
Rajabian, A., McCloskey, A. P., Jamialahmadi, T., Moallem, S. A., & Sahebkar, A. (2023) · Reviews in the Neurosciences · doi:10.1515/revneuro-2023-0005 · Cited by 7
Schettler, V. J. J., Ringel, J., Jacob, S., Julius, U., Klingel, R., Heigl, F., Roeseler, E., & Grützmacher, P. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.005 · Cited by 7
Giannessi, L., Lupo, M., Rossi, I., Martina, M. G., Vilella, A., Bodria, M., Giuliani, D., Zimetti, F., Zanotti, I., Potì, F., et al. (2023) · European journal of medicinal chemistry · doi:10.1016/j.ejmech.2023.116063 · Cited by 7
Zhang, A. M. C., Ziogos, E., Harb, T., Gerstenblith, G., & Leucker, T. M. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14272 · Cited by 7
Marquis‐Gravel, G., Bhatia, S., Brown, V., & Goodman, S. G. (2024) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2024.05.010 · Cited by 7
The past, present and future of lipidlowering therapy
Najam, O., Lambert, G. C., & Ray, K. K. (2015) · Clinical Lipidology · doi:10.2217/clp.15.40 · Cited by 7
Limitations of cholesterol lowering with PCSK9 inhibitors
Thompson, G. R. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30060-8 · Cited by 7
Recent Insights into Pharmacologic Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus
Purga, S. L., Sidhu, M. S., Farkouh, M. E., & Schulman‐Marcus, J. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6750-1 · Cited by 7
Jensen, J. S., Weeke, P. E., Bang, L. E., Høfsten, D. E., Ripa, M. S., Schjerning, A.-M., Theilade, J., Køber, L., Gislason, G., & Pallisgaard, J. L. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-022702 · Cited by 7
Hirayama, A., Yamashita, S., Ruzza, A., Inomata, H., Cyrille, M., Lu, C., Hamer, A. W., Yoshida, M., Kiyosue, A., & Teramoto, T. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0139 · Cited by 7
Target discovery using biobanks and human genetics
Hicks, M. A., Hou, C., Iranmehr, A., Marosi, K., & Kirkness, E. F. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.09.014 · Cited by 7
Preclinical discovery and development of evolocumab for the treatment of hypercholesterolemia
Khoury, É., Brisson, D., & Gaudet, D. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1704728 · Cited by 6
SATO, S. T., Akamine, Y., Kagaya, H., Saito, M., Inoue, T., Numakura, K., Habuchi, T., Satoh, S., & Miura, M. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00090-6 · Cited by 7
Duprez, D. A., Handelsman, Y., & Koren, M. J. (2020) · Vascular Health and Risk Management · doi:10.2147/vhrm.s261719 · Cited by 8
Self-citationKimura, T., Akahori, H., Tanaka, T., Yanaka, K., Yoshihara, N., Miki, K., Imanaka, T., Asakura, M., & Ishihara, M. (2022) · Journal of Cardiology · doi:10.1016/j.jjcc.2022.03.004 · Cited by 7
McEvoy, J. W., Whelton, S. P., & Blumenthal, R. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42973-3.00038-x · Cited by 6
The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
Seidah, N. G. (2015) · Global Cardiology Science and Practice · doi:10.5339/gcsp.2015.59 · Cited by 8
Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review
McClintick, D. J., & Giugliano, R. P. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000897 · Cited by 7
Self-citationRay, K. K., Gunn, L. H., Conde, L. G., Raal, F. J., Wright, R. S., Gosselin, N. H., Leiter, L. A., Köenig, W., Schwartz, G. G., & Landmesser, U. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117472 · Cited by 8
Self-citationDanek, B. A., Karatasakis, A., Madder, R. D., Muller, J. E., Madden, S., Banerjee, S., & Brilakis, E. S. (2016) · Current Cardiovascular Imaging Reports · doi:10.1007/s12410-015-9369-2 · Cited by 7
Lipid Management Guidelines from the Departments of Veteran Affairs and Defense: A Critique
Bennet, C. S., Dahagam, C., Virani, S. S., Martin, S. S., Blumenthal, R. S., Michos, E. D., & McEvoy, J. W. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.04.012 · Cited by 7
Novel Therapies for Familial Hypercholesterolemia
Parizo, J. T., Sarraju, A., & Knowles, J. W. (2016) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-016-0486-2 · Cited by 7
PCSK9: the Critical Role of Familial Hypercholesterolemia from Discovery to Benefit for all
Stein, E. A. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6690-1 · Cited by 7
Self-citationUsing human genetics to discover new therapeutic targets for plasma lipids
Cohen, J. C. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12521 · Cited by 7
Choi, J., Khan, A. M., Jarmin, M., Goldenberg, N., Glueck, C. J., & Wang, P. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0493-7 · Cited by 7
Clinical outcomes of PCSK9Is: a meta-analysis of randomized clinical trials
Ghadban, R., Enezate, T. H., Omran, J., Almourani, R., Singla, A., & Balla, S. (2017) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2017.08.16 · Cited by 7
Chróinín, D. N., Chróinín, C. N., Akijian, L., Callaly, E. L., Hannon, N., Kelly, L., Marnane, M., Merwick, Á., Sheehan, O. C., Horgan, G., et al. (2018) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-018-1739-8 · Cited by 7
Elseweidy, M. M., El-Swefy, S. E., Younis, N. N., & Tarek, S. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-04836-1 · Cited by 7
Cataracts and statins. A disproportionality analysis using data from VigiBase
Saint-Gerons, D. M., Cortez, F. B., López, G. J., Castro, J. L., & Tabarés‐Seisdedos, R. (2019) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2019.104509 · Cited by 7
Baum, S. J., Wade, R. L., Xiang, P., Arellano, J., Olmos, C. C., Nunna, S., Chen, C., Carter, C. M., & Desai, N. R. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s216606 · Cited by 7
Chan, D. C., Pang, J., & Watts, G. F. (2016) · Springer eBooks · doi:10.1007/978-3-319-11251-0_30 · Cited by 10
Belalcazar, L. M., Papandonatos, G. D., Erar, B., Peter, I., Alkofide, H., Balasubramanyam, A., Brautbar, A., Kahn, S. E., Knowler, W. C., Ballantyne, C. M., et al. (2015) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.115.001192 · Cited by 8
Self-citationBiomarkers in drug development
Schuck, R. N., Delfino, J. G., Leptak, C., & Wagner, J. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819869-8.00029-x · Cited by 7
Grundy, S. M. (2018) · Endocrinology · doi:10.1007/978-3-319-44433-8_3 · Cited by 7
Hyperlipidemia and cardiovascular disease
Burkhardt, R. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000221 · Cited by 7
Robinson, J. G. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.040 · Cited by 7
Self-citationLi, B., Chen, Y., Zhang, Y., Qian, M., Shan, Q., Qian, J., & Guo, J. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2468855 · Cited by 6
The evolving therapeutic landscape of PCSK9 inhibition
Mansfield, B. S., Bene-Alhasan, Y. O., Ballantyne, C. M., & Raal, F. J. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120670 · Cited by 7
Self-citationEchevarría, A. B., García-Díaz, J. D. D., Caixàs, A., Plana, N., Corral, M. Á. R., Bridges, I. M., Dhalwani, N. N., Menchen, S. G., & Ray, K. K. (2023) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2023.04.004 · Cited by 6
Rentería, M. A., McClure, L. A., CALLAS, P. W., LaBode-Richman, V. M., Kroll, D. S., Manly, J. J., Zakai, N. A., Unverzagt, F. W., & Cushman, M. (2023) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2023.102170 · Cited by 6
Zhang, Y., Zhang, A., Wu, Y., Zhang, Y., Hu, W., Chen, P., Chen, K., & Ding, J. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2409270 · Cited by 6
Targeting NPC1 in Renal Cell Carcinoma
Fazliyeva, R., Makhov, P. B., Uzzo, R. G., & Kolenko, V. M. (2024) · Cancers · doi:10.3390/cancers16030517 · Cited by 8
Zhang, A. M. C., Ziogos, E., Harb, T., Gerstenblith, G., & Leucker, T. M. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14273 · Cited by 6
Akinlonu, A. A., Boffa, M. B., Lyu, C., Zhong, J., Jindal, M., Fadzan, M., Garshick, M. S., Schwartzbard, A. Z., WEINTRAUB, H. S., Bredefeld, C., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.11.008 · Cited by 7
Cheng, J., Wang, H., Song, C., Qiao, Z., Bian, X., Yin, D., Feng, L., Zhu, C., Yang, M., Gao, G., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.100965 · Cited by 6
Monoclonal Antibodies for Lipid Management
Feinstein, M. J., & Lloyd‐Jones, D. M. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0593-2 · Cited by 6
Impact of diet and exercise on proprotein convertase subtilisin/kexin 9: A mini-review
Saely, C. H., & Drexel, H. (2016) · Vascular Pharmacology · doi:10.1016/j.vph.2016.10.003 · Cited by 6
Lipoprotein(a) in nephrological patients
Hohenstein, B. (2017) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-017-0086-z · Cited by 6
A safety evaluation of evolocumab
Roth, E. M. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1389892 · Cited by 7
Latest Updates on Lipid Management
Egom, E. E. A., Pharithi, R. B., Hesse, S., Starr, N., Armstrong, R. L., Sulaiman, H. M., Gazdíková, K., Mozos, I. M., Čaprnda, M., Kubatka, P., et al. (2019) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-019-00306-8 · Cited by 5
Evolocumab’s Long-Term Mortality Risk Unclear Due to Shortened Follow-Up of FOURIER
van Bruggen, F. H., & Luijendijk, H. J. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00480-y · Cited by 6
Goicoechea, M., Álvarez, V., Segarra, A., Polaina, M., Martín-Reyes, G., Robles, N. R., Escudero, V., Orellana, C., Granell, S. B., de Juan-Ribera, J., et al. (2021) · Nefrología · doi:10.1016/j.nefro.2021.06.004 · Cited by 6
Metadata
- Authors
- Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., Scott, R., Koren, M. J., & Stein, E. A.
- Affiliations
- University of Iowa (US)
- Harvard University (US)
- University of the Witwatersrand (ZA)
- University of Cape Town (ZA)
- Houston Methodist (US)
- Amgen (United States) (US)
- Jacksonville Center for Clinical Research (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-04-16
- Volume
- 372
- Issue
- 16
- Pages
- 1500-1509
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4238580056
- Semantic Scholar
- 3a2aa2d61647c779adc7c8fa42c75fb373940128
- Cited by
- 1,509
- References
- 26
- Citations by year
- 2026: 44 · 2025: 54 · 2024: 71 · 2023: 73 · 2022: 88 · 2021: 91 · 2020: 104 · 2019: 148 · 2018: 152 · 2017: 261 · 2016: 277 · 2015: 141
- FWCI
- 279.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- evolocumab, PCSK9 inhibitors, LDL cholesterol lowering, cardiovascular events, lipid-lowering therapy, drug efficacy, drug safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
